Psilocybin (drug)
DrugOne arm will receive psilocybin 25 mg
Other names: Placebo
NCT Number: NCT07433452
In this study, participants will received either psilocybin (the active ingredient found in certain mushrooms) or an inactive placebo (a look-alike tablet with no active drug). The psilocybin is supplied by Filament Health (Burnaby, British Columbia).
After psilocybin ingestion, the body quickly converts it into psilocin, which is the form that produces the temporary psychological effects. Psilocin mainly works by interacting with serotonin receptors in the brain, especially a type called the 5-HT2A receptor.
This study will be done in healthy volunteers using a single oral dose of 25 mg (one tablet by mouth), consistent with doses used in previous clinical research.
The goal is to understand the biological, psychological, and high-density EEG (hd-EEG) changes that can happen after a one-time dose of psilocybin.
Trial opening soon.
Get Notified21 year–65 year
All sexes
Interventional
Phase 1
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One arm will receive psilocybin 25 mg
Other names: Placebo
One group will receive a placebo pill
Time frame: Baseline to 7 days post-dose
Plasmatic Endocannabinoids
Time frame: Baseline to 7 days post-dose
Tryptophan Pathways
Time frame: Baseline to 7 days post-dose
Interpersonal Reactivity Index (IRI, 28 items): A multidimensional assessment of empathy. There are 4 subitems measuring Perspective Taking, the tendency to spontaneously adopt the psychological point of view of others; Fantasy, one's tendency to transpose themselves imaginatively into the feelings and actions of fictitious characters; Empathic Concern, feelings of sympathy and concern for unfortunate others; and Personal Distress, feelings of personal anxiety and unease in tense interpersonal settings.
Time frame: Baseline to 7 days post-dose
The Multifaceted Empathy Test (MET) is used to measure empathy competence. It consists of a series of photorealistic images showing people in emotionally charged situations. The test yields two primary sub-scores: 1) Cognitive Empathy: Participants infer the mental state of the person in the image; 2) Emotional Empathy: Participants rate their own emotional reaction to the image (e.g., "How much do you feel for this person?"). Responses are typically recorded on a Likert scale (e.g., 1-9), where 1 represents "not at all" and 9 represents "very strong." Scores are summed for each component, with higher scores indicating higher levels of empathy.
Time frame: From Baseline to 1 week after treatment
POMS is a 65 item scales which assesses transient mood states in individuals 18 and older. The scale has been widely used within clinical psychiatric and psychotherapeutic environments for the purpose of assessing individuals' mood-related treatment responses. There are 6 subscales, including Tension-Anxiety, Depression, Anger-Hostility, Fatigue, Confusion-Bewilderment, and Vigour-Activity. The scale has been validated widely and possesses test-retest reliability.
Time frame: Before the administration of psilocybin or placebo and during the effect of the drug (about 6 hours).
High-density electroencephalography (hd-EEG) is a non-invasive method used to record electrical brain activity from multiple electrodes placed on the scalp. This technique provides detailed information about brain function and neural activity. In this study, hd-EEG will be used to assess changes in brain activity following study drug administration. The procedure is painless and involves wearing an electrode cap for approximately 20-40 minutes.
Time frame: Baseline and 1 week after treatment
DNA methylation and histone modification) analysis of genes involved in spirituality and resilience
Contact information is provided by the study sponsor or research team.
Gabriella Gobbi
Other
Acronym: PSILOBIOMARKER
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07723118
Healthy Participants
Anaheim, California, United States
View Trial DetailsNCT07723833
Body Weight, Diabetes Mellitus
Glendale, California, United States
View Trial DetailsNCT06951880
Healthy Participants
Glendale, California, United States
View Trial DetailsNCT07593222
Behavior, Behavioral Symptoms
Belmont, Massachusetts, United States
View Trial Details